Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in ...

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease. Captions are auto-generated.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before surgery rose 16-fold among patients undergoing metabolic and bariatric surgery from 2020 to 2024.

Please provide your email address to receive an email when new articles are posted on . Results showed 14 days may be the optimal cutoff for glucagon-like peptide-1 receptor agonists prior to hip or ...

GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients who received glucagon-like peptide-1 receptor ...

New research suggests that diabetes and weight-loss drugs known as GLP-1 receptor agonists may also help treat alcohol and drug addiction. A widely used group of medications originally developed to ...

Treatment with GLP-1 RAs was linked to decreased risks for all-cause mortality and MACE in patients with psoriasis when compared with other antidiabetic or obesity drugs.

MASLD is one of the pressing public health issues; yet, unfortunately, there is a scarcity of available pharmacological management options. GLP-1RAs have transformed the treatment landscape for ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident neovascular ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay News) ...